See All Slides - tctmd.com

Slides

Presentation TCT 2018

Ultra-Thin Strut DES: A Meaningful Advance?

Presenter: Renu Virmani, Clemens von Birgelen, Sripal Bangalore

September 22, 2018

Presentation TCT 2018

The Voice of Reason: Why a Randomized Trial is Necessary to Decide if Surgery or TAVR are Preferred in BAV Patients!

Presenter: Joseph E. Bavaria, Horst Sievert, Hasan Jilaihawi

September 22, 2018

Presentation TCT 2018

Major Learnings From IABP-Shock II and CULPRIT-Shock

Presenter: Cindy L. Grines, E. Magnus Ohman, Holger Thiele

September 22, 2018

Presentation TCT 2018

A Structural Interventionalist Perspective on BAV Treatment: The Next TAVR Frontier Almost All Patients are TAVR Candidates

Presenter: Joseph E. Bavaria, Horst Sievert, Mathew Williams

September 22, 2018

Presentation TCT 2018

Highlights From the Updated PAD Guidelines and SCAI AUC

Presenter: Jay S. Giri, Sahil A. Parikh, Douglas E. Drachman

September 22, 2018

Presentation TCT 2018

Can Contemporary DES Be Improved by Altering the Drug, Polymer, Alloy or Construction?

Presenter: Renu Virmani, Clemens von Birgelen, David E. Kandzari

September 22, 2018

Presentation TCT 2018

Keynote Lecture: Cardiovascular Innovation: Reconciling Todays Clinical Needs With the Future of Medical Technologies

Presenter: Louis A. Cannon, Juan F. Granada, Sanjeev Bhavnani

September 22, 2018

Presentation TCT 2018

Acute Cardiogenic Shock: Pathophysiology and Treatment Goals

Presenter: Cindy L. Grines, E. Magnus Ohman, Timothy D. Henry

September 22, 2018

Presentation TCT 2018

A CT Imaging Perspective on BAV Treatment: Which Patients are Poor Candidates for TAVR

Presenter: Joseph E. Bavaria, Horst Sievert, Jonathon A. Leipsic

September 22, 2018

Presentation TCT 2018

Announcing the Jon DeHaan Foundation Award for Interventional Innovation

Presenter: Louis A. Cannon, Juan F. Granada, Robert S. Schwartz

September 22, 2018

Advertisement

Slides

Ultra-Thin Strut DES: A Meaningful Advance?

The Voice of Reason: Why a Randomized Trial is Necessary to Decide if Surgery or TAVR are Preferred in BAV Patients!

Major Learnings From IABP-Shock II and CULPRIT-Shock

A Structural Interventionalist Perspective on BAV Treatment: The Next TAVR Frontier Almost All Patients are TAVR Candidates

Highlights From the Updated PAD Guidelines and SCAI AUC

Can Contemporary DES Be Improved by Altering the Drug, Polymer, Alloy or Construction?

Keynote Lecture: Cardiovascular Innovation: Reconciling Todays Clinical Needs With the Future of Medical Technologies

Acute Cardiogenic Shock: Pathophysiology and Treatment Goals

A CT Imaging Perspective on BAV Treatment: Which Patients are Poor Candidates for TAVR

Announcing the Jon DeHaan Foundation Award for Interventional Innovation

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content